Viewing StudyNCT02834780

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 8:51 AM
Last Modification Date: 2024-10-26 @ 12:06 PM
Study NCT ID: NCT02834780
Status: COMPLETED
Last Update Posted: 2023-11-13
First Post: 2016-07-13
Brief Title: Phase 1 Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Sponsor: H3 Biomedicine Inc
Organization: Eisai Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Liver Cancer
Liver Neoplasms
Hepatic Cancer
Hepatic Carcinoma
Keywords:
Name View
Fibroblast growth factor 19 FGF19 View
Advanced Hepatocellular Carcinoma View
H3B-6527 View
Fibroblast growth factor receptor 4 FGFR4 View